Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AS MDI
PT007 · 1 trial · 1 indication
Forced expiratory volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation
| Arm | Type | Description |
|---|---|---|
| AS MDI | EXPERIMENTAL | AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation |
| Proventil | ACTIVE_COMPARATOR | Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation |
| Name | Type | Description |
|---|---|---|
| AS MDI | DRUG | AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation |
| Proventil | DRUG | Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation |
Inclusion Criteria: * Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis * Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low to me...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
PT007 is an investigational inhaled therapy being studied for the treatment of asthma. It is a small molecule delivered as a metered dose inhaler and has been evaluated in a Phase 2 clinical trial in adults with asthma. It is not described as an approved treatment.
PT007 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. The company sponsored the Phase 2 study of the asset in asthma, which was conducted in the United States.
PT007 is in Phase 2 development. One Phase 2 trial in asthma has been completed, and no active trials of PT007 are currently listed. The program remains investigational and has not been described as approved by the FDA.
PT007 has been studied in NCT03371459, a completed Phase 2 trial titled Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension Compared to Proventil as an Active Control in Subjects With Asthma. The trial enrolled 46 adults in the United States.
Yes. PT007 is also known as AS MDI, albuterol sulfate metered dose inhaler, and albuterol metered dose inhaler. These names refer to the same AstraZeneca asset, an inhaled small molecule formulation studied in asthma under the NCT03371459 Phase 2 trial.
NCT03371459 was a randomized, active-controlled Phase 2 trial of PT007 in adults with asthma, with Proventil serving as the active control. It enrolled 46 participants, was not double-blind, and did not select patients by biomarker. The study has been completed.